Stockreport

PADCEV™ Plus KEYTRUDA™, Given Before and After Surgery, Cuts the Risk of Recurrence, Progression or Death by 60% and the Risk of Death by 50% for Certain Patients with Bladder Cancer [Yaho...

ASTELLAS PHARMA UNSP/ADR  (ALPMY) 
NASDAQ:AMEX Investor Relations: astellas.com/jp/en/investors
PDF Unprecedented survival results from pivotal Phase 3 EV-303 trial show potential for PADCEV plus KEYTRUDA to redefine standard of care TOKYO and NEW YORK Oct. 18, 2025 [Read more]